RxDoctor Payments Data

Lacey Eichhorst, APRN

Family · Carson City, NVNPI 1154085132

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 47 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$214
  • Novo Nordisk$176
  • Lilly USA, LLC$159
  • AbbVie$109
  • Astellas Pharma US Inc$86
  • Merck$79
  • plus $231 from 10 others

What the payments were for

  • Food & beverage$1,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$53,146
Medicare patients
246
Services billed
802

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide23$28,577
JardianceEmpagliflozin11$12,224
MounjaroTirzepatide11$11,545
EliquisApixaban16$11,331
SynthroidLevothyroxine Sodium53$4,094
Sertraline Hcl63$2,295
Estradiol17$1,742
Albuterol Sulfate HfaAlbuterol Sulfate39$1,660
Fluticasone Propionate14$1,320
Atorvastatin Calcium104$1,240
Gabapentin80$1,092
Bupropion XlBupropion Hcl27$1,014
Levothyroxine Sodium157$998
Olmesartan Medoxomil12$970
Duloxetine Hcl28$864

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$176$28,57723 claims
Boehringer IngelheimJardiance$16$12,22411 claims
Lilly USA, LLCMounjaro$159$11,54511 claims
PfizerEliquis$214$11,33116 claims
AbbVieSynthroid$109$4,09453 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.

Other family in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →